# Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

> **NCT05477576** · PHASE3 · RECRUITING · sponsor: **RayzeBio, Inc.** · enrollment: 338 (estimated)

## Conditions studied

- GEP-NET
- Gastroenteropancreatic Neuroendocrine Tumor
- Gastroenteropancreatic Neuroendocrine Tumor Disease
- Neuroendocrine Tumors
- Carcinoid
- Carcinoid Tumor
- Pancreatic NET

## Interventions

- **DRUG:** RYZ101
- **DRUG:** Everolimus
- **DRUG:** Sunitinib
- **DRUG:** Octreotide
- **DRUG:** Lanreotide

## Key facts

- **NCT ID:** NCT05477576
- **Lead sponsor:** RayzeBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-24
- **Primary completion:** 2026-12
- **Final completion:** 2030-12
- **Target enrollment:** 338 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05477576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05477576, "Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05477576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*